Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Maytansine × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Salivary Gland Neoplasms 1

Interventions

Specimen Handling 153 Magnetic Resonance Spectroscopy 125 Biopsy 99 pembrolizumab 83 Carboplatin 69 Cyclophosphamide 67 Paclitaxel 57 Cisplatin 54 Nivolumab 49 venetoclax 44 Radiotherapy 38 Gemcitabine 36 fludarabine 33 durvalumab 33 Rituximab 33 Dexamethasone 33 Bevacizumab 33 olaparib 30 atezolizumab 30 Prednisone 29 Oxaliplatin 29 X-Rays 28 Radiation 28 Ipilimumab 27 Cytarabine 27 Fluorouracil 25 Etoposide 25 Docetaxel 25 Doxorubicin 24 Azacitidine 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04620187 2026-02-24

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Dana-Farber Cancer Institute

Phase 2 Recruiting

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡